Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 18, 2024
Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC InvestigationChan Xiang, Xinze Lv, Ke Chen, et al.
The Oncologist|April 25, 2021
HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric AdenocarcinomaXiao-Dong Jiao, Ke Liu, Ying Wu, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2021
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patientsXi Chen, Liangjie Fang, Yanping Zhu, et al.
Med (New York, N.Y.)|March 24, 2026
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trialLinong Ji, Hongwei Jiang, Zhifeng Cheng, et al.
Cancer Science|March 7, 2023
Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancerRui Han, Yimin Zhang, Tianhu Wang, et al.
Cancer Medicine|November 7, 2022
The rational application of liquid biopsy based on next-generation sequencing in advanced non-small cell lung cancerChenglong Zhao, Jianghua Li, Yongchang Zhang, et al.
Nature|December 17, 2025
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetesLixin Guo, Bo Zhang, Xia Xue, et al.
The Oncologist|May 31, 2022
Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901)Wenying Peng, Liming Cao, Likun Chen, et al.
Advances in Therapy|January 27, 2026
Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 TrialQing Yang, Bin Yang, Heng Gu, et al.
Ophthalmology Science|October 6, 2025
Efficacy and Safety of Efdamrofusp Alfa with Personalized Dosing Intervals in Neovascular Age-Related Macular Degeneration: A Phase II TrialTong Li, Shiqi Yang, Qinghuai Liu, et al.
Pageof 5